Type 2 diabetes treatment: The findings suggest that TMA may help recalibrate harmful metabolic responses triggered by poor dietary habits.

Diabetes type 2, can be caused by obesity and occurs when adults become resistant to the hormone insulin. Type 1 diabetes, mostly diagnosed...

Mayo Clinic scientists have made a breakthrough in type 1 diabetes treatment. They discovered a 'sugar coating' method. This protects insul...

Wockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its b...

The invention of insulin in 1922 marked a turning point in medical history. Sparked by Frederick Banting’s idea and tested on diabetic pati...

Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no lon...

The findings have been published in the journal Cell Metabolism.

Global Head of Market Access & Policy, Biocon Biologics, Alexander Zach, said:"Given our extensive experience in providing affordable insul...

Researchers have identified cells that can take over functions of damaged or missing insulin-producing cells.

Melbourne, Sep 13 (IANS) The venom of a carnivorous sea snail could hold the key for artificial, fast-acting insulin for diabetes patients,...

Researchers have identified a biomarker in pre-diabetic individuals that could help prevent them from developing Type 2 diabetes.

Biocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...

Indian scientists have developed a long-sought insulin pill that could spare millions of diabetics around the world the pain of daily jabs.

Four months after its partnership with Pfizer fell through, Biocon is now close to inking a deal with US-based biopharmaceuticals giant Bri...

In an interview with ET, Novo Nordisk's president and CEO Lars Rebien Sorensen talks of the growing transfer of accounting and patenting wo...

After the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.

Wockhardt is likely to out-license some of its research molecules to global pharma companies.